Test ID STER Sterols, Plasma
Useful For
Investigation of possible desmosterolosis (desmosterol reductase deficiency) and sitosterolemia
Special Instructions
Method Name
Gas Chromatography-Mass Spectrometry (GC-MS)/Gas Chromatography-Flame Ionization Detection (GC-FID)
Reporting Name
Sterols, PSpecimen Type
PlasmaCollection Container/Tube:
Preferred: Green top (sodium heparin)
Acceptable: EDTA
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Fasting (12 hours or more, infants just before next feeding).
2. Spin down within 45 minutes of draw.
Additional Information: Patient's age and sex are required.
Forms:
1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (Supply T576) is available in Special Instructions.
2. If not ordering electronically, complete, print, and send a Neurology Test Request Form-General (T732) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/neurology-request-form.pdf).
Specimen Minimum Volume
0.2 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Plasma | Frozen (preferred) | 90 days |
Refrigerated | 90 days |
Clinical Information
Cholesterol plays an essential role in many cellular and developmental processes. In addition to its role as a membrane lipid, it is the precursor to numerous molecules that play an important role in cell growth and differentiation, protein glycosylation, and signaling pathways. The biosynthesis of cholesterol and its subsequent conversion to other essential compounds is complex, involving a number of intermediates and enzymes. Disorders that result from a deficiency of these enzymes lead to an accumulation of specific intermediates and inhibit the formation of important biomolecules. Clinical findings common to cholesterol biosynthesis disorders include congenital skeletal malformations, dysmorphic facial features, psychomotor retardation, and failure to thrive.
The clinical phenotype of desmosterolosis (desmosterol reductase deficiency) is similar to Smith-Lemli-Opitz (SLO) syndrome (7-dehydrocholesterol reductase deficiency) and typically involves the central nervous system (CNS). Its biochemical marker is the elevation of desmosterol in plasma, tissue, and cultured cells.
Sitosterolemia is a rare autosomal recessive disorder caused by mutations in the ATP-binding cassette (ABC) transporter genes, ABCG5 and ABCG8, which abnormally enhance the absorption of plant sterols and cholesterol from the intestines. Patients often present with hematologic abnormalities and tendon and tuberous xanthomas as well as premature coronary artery disease. A biochemical diagnosis of sitosterolemia is made by documenting elevations of the plant sterols sitosterol and campesterol in plasma or serum.
Reference Values
DESMOSTEROL
0.0-5.0 mg/L
LATHOSTEROL
0.0-7.0 mg/L
CAMPESTEROL
0.0-7.0 mg/L
SITOSTEROL
0.0-5.0 mg/L
Cautions
Reference ranges were derived using fasting specimens from healthy individuals. Sitosterol and campesterol values may be mildly elevated in individuals whose diets include foods with high concentrations of plant sterols, such as some vegetable oils and infant formulas.
Day(s) Performed
Varies; 2 p.m.
Report Available
2 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
82542